Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?

BACKGROUND/AIM: PD-1 (programmed death-1) is an immune checkpoint receptor that modulates T-cell activity in peripheral tissues via interaction with its ligands, PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2). Tumor cells upregulate PD-L1 or PD-L2 to inhibit this T lymphocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: KORKMAZ, Serdal, ERDEM, Selahattin, AKAY, Ebru, TAŞDEMİR, Erdem Arzu, KARAMAN, Hatice, KEKLİK, Muzaffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350792/
https://www.ncbi.nlm.nih.gov/pubmed/30761875
http://dx.doi.org/10.3906/sag-1706-194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350792/
https://www.ncbi.nlm.nih.gov/pubmed/30761875
http://dx.doi.org/10.3906/sag-1706-194

Ejemplares similares